Quantbot Technologies LP Invests $3.61 Million in Hologic, Inc. $HOLX

Quantbot Technologies LP purchased a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 53,503 shares of the medical equipment provider’s stock, valued at approximately $3,611,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company raised its stake in Hologic by 294.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock valued at $718,223,000 after purchasing an additional 8,227,318 shares during the period. Invesco Ltd. grew its holdings in shares of Hologic by 72.5% during the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock valued at $543,486,000 after buying an additional 3,505,828 shares in the last quarter. Geode Capital Management LLC raised its position in Hologic by 1.7% during the second quarter. Geode Capital Management LLC now owns 5,828,325 shares of the medical equipment provider’s stock valued at $378,209,000 after buying an additional 97,142 shares during the period. Black Creek Investment Management Inc. lifted its stake in Hologic by 26.1% in the 2nd quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock worth $262,453,000 after acquiring an additional 832,444 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Hologic by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 3,090,306 shares of the medical equipment provider’s stock worth $201,364,000 after acquiring an additional 66,453 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on HOLX. Evercore cut Hologic from an “outperform” rating to an “in-line” rating and lowered their target price for the company from $79.00 to $78.00 in a research note on Monday, January 5th. Morgan Stanley raised their price target on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Finally, BNP Paribas Exane lowered shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price for the company. in a research note on Friday, November 21st. Two equities research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $78.42.

Hologic Trading Up 0.2%

Shares of NASDAQ:HOLX opened at $75.36 on Monday. The stock has a market capitalization of $16.82 billion, a PE ratio of 31.40, a P/E/G ratio of 2.24 and a beta of 0.72. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $75.49. The firm has a fifty day moving average price of $74.95 and a 200 day moving average price of $72.16. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the business earned $0.87 earnings per share. Hologic’s quarterly revenue was up 2.5% on a year-over-year basis. Analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.